Caristo Diagnostics pricing
No price, per study fee or license structure is published; sales start from a conversation. CaRi-Heart, FDA authorized through De Novo in July 2026 with US commercial launch starting in the third quarter of 2026, carries Category III CPT codes 0992T and 0993T from January 2026; Category III codes have no set national payment, so coverage is decided payer by payer. CaRi-Plaque, cleared in February 2025, falls under the Category I code for AI plaque analysis. Those describe what a provider can bill, not Caristo's price. The per study price of each product and which payers cover CaRi-Heart are not published.
How Caristo Diagnostics pricing works
- Pricing model
- Not published; payer billing codes documented (Category III for CaRi-Heart, Category I for plaque analysis)
Caristo Diagnostics pricing against its alternatives
Published prices for Caristo Diagnostics and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- CCaristo DiagnosticsNo published price
- HHeartflowNo published price
- CCleerlyNot published; reimbursement pathway documented
- EElucidNo published price
- AArtryaSubscription plus fee per scan. One contract value published (US$0.6M over five years)
- CCircle Cardiovascular ImagingNo published price
- CCaris Life SciencesNo published price
- VViz.aiNo published price
- BBrainomixNo published price
Caristo Diagnostics pricing, answered
How much does Caristo Diagnostics cost?
Caristo Diagnostics does not publish a price. CaRi-Heart, FDA authorized through De Novo in July 2026 with US commercial launch starting in the third quarter of 2026, carries Category III CPT codes 0992T and 0993T from January 2026; Category III codes have no set national payment, so coverage is decided payer by payer. CaRi-Plaque, cleared in February 2025, falls under the Category I code for AI plaque analysis.